表紙:融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2022年~2031年)
市場調査レポート
商品コード
1208546

融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2022年~2031年)

Fusion Inhibitors Market (Indication: HIV/AIDS and COVID-19; and Route of Administration: Parenteral and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

出版日: | 発行: Transparency Market Research | ページ情報: 英文 185 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.79円
融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2022年~2031年)
出版日: 2022年12月08日
発行: Transparency Market Research
ページ情報: 英文 185 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の融合阻害剤市場について調査し、市場の概要とともに、2022年~2031年の予測、投与経路別、適応症別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー:世界の融合阻害剤市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の融合阻害剤市場の分析と予測、2017年~2031年

第5章 主な洞察

第6章 世界の融合阻害剤市場の分析と予測、投与経路別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測、投与経路別、2017年~2031年
    • 経口
    • 非経口
  • 市場の魅力分析、投与経路別

第7章 世界の融合阻害剤市場の分析と予測、適応症別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測、適応症別、2017年~2031年
    • HIV/AIDS
    • COVID-19
  • 市場の魅力分析、適応症別

第8章 世界の融合阻害剤市場の分析と予測、流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測、流通チャネル別、2017年~2031年
    • 小売薬局
    • オンライン薬局
    • その他
  • 市場の魅力分析、流通チャネル別

第9章 世界の融合阻害剤市場の分析と予測、地域別

  • 主な調査結果
  • 市場価値予測、地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析、地域別

第10章 北米の融合阻害剤市場の分析と予測

第11章 欧州の融合阻害剤市場の分析と予測

第12章 アジア太平洋の融合阻害剤市場の分析と予測

第13章 ラテンアメリカの融合阻害剤市場の分析と予測

第14章 中東・アフリカの融合阻害剤市場の分析と予測

第15章 競合情勢

  • 市場参入企業-競合マトリクス
  • 市場シェア/ランキング分析、企業別、2021年
  • 企業プロファイル
    • Bristol-Myers Squibb Company
    • PeptidePharma
    • Incyte
    • Astrazeneca
    • ViiV Healthcare Limited
    • Frontier Bio Corporation
    • Trimeris, Inc.
    • Progenics Pharmaceuticals
    • Schering-Plough(Merck &Co.)
    • Biogen
    • Vanderbilt University
    • Genentech
図表

List of Tables

  • Table 01: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 02: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by 2017-2031, by Indication
  • Table 03: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 07: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 08: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 11: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 16: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 24: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Fusion Inhibitors Market Value Share, by Route of Administration, 2021
  • Figure 03: Global Fusion Inhibitors Market Value Share, by Indication, 2021
  • Figure 04: Global Fusion Inhibitors Market Value Share, by Distribution Channel, 2021
  • Figure 05: Global Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 06: Global Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 09: Global Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 10: Global Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 11: Global Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 12: Global Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 13: Global Fusion Inhibitors Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 14: Global Fusion Inhibitors Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 15: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: North America Fusion Inhibitors Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 17: North America Fusion Inhibitors Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 18: North America Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 19: North America Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 20: North America Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 21: North America Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 22: North America Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 23: North America Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 24: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: Europe Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 26: Europe Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 27: Europe Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 28: Europe Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 29: Europe Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 30: Europe Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 31: Europe Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 32: Europe Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 37: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 38: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 39: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 40: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 43: Latin America Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 45: Latin America Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 46: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 47: Latin America Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 48: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 49: Latin America Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 50: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 54: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 55: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 56: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 57: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 58: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 59: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Company Share Analysis, 2021
目次
Product Code: TMRGL85266

The report provides revenue of the global fusion inhibitors market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fusion inhibitors market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fusion inhibitors market.

The report delves into the competitive landscape of the global fusion inhibitors market. Key players operating in the global fusion inhibitors market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global fusion inhibitors market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fusion Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fusion Inhibitors Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Mergers & Acquisitions
  • 5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. Drug Pricing Analysis
  • 5.4. Pipeline Analysis
  • 5.5. Covid-19 Pandemic Impact on the Industry

6. Global Fusion Inhibitors Market Analysis and Forecast, by Route of Administration

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Attractiveness Analysis, by Route of Administration

7. Global Fusion Inhibitors Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. HIV/AIDS
    • 7.3.2. COVID-19
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Fusion Inhibitors Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Online Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Fusion Inhibitors Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Fusion Inhibitors Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. HIV/AIDS
    • 10.3.2. COVID-19
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Retail Pharmacies
    • 10.4.2. Online Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Route of Administration
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Fusion Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.2.1. Oral
    • 11.2.2. Parenteral
  • 11.3. Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. HIV/AIDS
    • 11.3.2. COVID-19
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Retail Pharmacies
    • 11.4.2. Online Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Route of Administration
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Fusion Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.2.1. Oral
    • 12.2.2. Parenteral
  • 12.3. Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. HIV/AIDS
    • 12.3.2. COVID-19
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Retail Pharmacies
    • 12.4.2. Online Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Route of Administration
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Fusion Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.2.1. Oral
    • 13.2.2. Parenteral
  • 13.3. Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. HIV/AIDS
    • 13.3.2. COVID-19
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Retail Pharmacies
    • 13.4.2. Online Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Route of Administration
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Fusion Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.2.1. Oral
    • 14.2.2. Parenteral
  • 14.3. Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. HIV/AIDS
    • 14.3.2. COVID-19
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Retail Pharmacies
    • 14.4.2. Online Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Route of Administration
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share/Ranking Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Bristol-Myers Squibb Company
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Strategic Overview
    • 15.3.2. PeptidePharma
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Strategic Overview
    • 15.3.3. Incyte
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Strategic Overview
    • 15.3.4. Astrazeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Strategic Overview
    • 15.3.5. ViiV Healthcare Limited
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Strategic Overview
    • 15.3.6. Frontier Bio Corporation
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Strategic Overview
    • 15.3.7. Trimeris, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Strategic Overview
    • 15.3.8. Progenics Pharmaceuticals
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Strategic Overview
    • 15.3.9. Schering-Plough (Merck & Co.)
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Strategic Overview
    • 15.3.10. Biogen
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Strategic Overview
    • 15.3.11. Vanderbilt University
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Strategic Overview
    • 15.3.12. Genentech
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Strategic Overview